Business
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million
CULVER CITY, Calif., May 07, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), a biotechnology company, announced financial and operational highlights for the fiscal quarter ended March 31, 2026. The Company reported net product revenue of approximately $44.2 million during the three months ended March 31, 2026, with net product revenue growth in every quarter since ANKTIVA’s commercial launch, including a 168% increase over Q1 2025. This builds on full-year 2025 net product revenue of $113.0 million, a 7
About this update from Immunitybio, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/24df2c99581d2a74d7b827e195cd7806"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7JkGSD3iGjy6IPsUTJBRfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MA--/https://media.zenfs.com/en/business-wire.com/24df2c99581d2a74d7b827e195cd7806","width":480,"height":270},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/BZZKQo3Zo2mD_vMkSBCzdA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTM2MA--/https://media.zenfs.com/en/business-wire.com/24df2c99581d2a74d7b827e195cd7806","width":480,"height":270}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Q1 2026 Revenue Growth with Continued Strong Sales Momentum: $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 and up 15% from Q4 2025","length":167,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"ANKTIVA® Unit Growth: 168% increase in unit sales volume in Q1 2026 compared to Q1 2025","length":87,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"ANKTIVA Regulatory Update: ANKTIVA is now approved or authorized across five regulatory jurisdictions, representing approximately 34 countries, including first approval in Asia by the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People’s Republic of China. Commercial availability achieved within two months of announcing MENA partnership with Biopharma and Cigalah Healthcare.","length":426,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash Position: $380.9 million in cash, cash equivalents and marketable securities as of March 31, 2026, up from $242.8 million as of December 31, 2025.","length":151,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Pivotal BCG-Naïve CIS trial (QUILT-2.005): Fully enrolled, with the Independent Data Monitoring Committee (IDMC) confirming no additional enrollment is required. A supplemental BLA (sBLA) submission is on track for 2026","length":219,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"BCG-Unresponsive NMIBC with Papillary-Only Disease Category 2A NCCN® Recommendation: NCCN Clinical Practice Guidelines in Oncology have been updated to include ANKTIVA plu...